PF-06669571 In Subjects With Idiopathic Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

May 13, 2016

Study Completion Date

May 13, 2016

Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG

PF-06669571

1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days

DRUG

Placebo

Placebo

Trial Locations (9)

30331

Atlanta Center for Medical Research, Atlanta

33009

MD Clinical, Hallandale

33024

QPS-MRA, LLC (Broward Research Group), Hollywood

33143

Qps-Mra Llc, South Miami

QPS-MRA, LLC (Miami research Associates), South Miami

QPS-MRA, LLC (MRA Clinical Research), South Miami

45255

CTI Clinical Research Center, Cincinnati

06511

Pfizer New Haven Clinical Research Unit, New Haven

08053

CRI Worldwide, LLC, Marlton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02565628 - PF-06669571 In Subjects With Idiopathic Parkinson's Disease | Biotech Hunter | Biotech Hunter